Cargando…

Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma

Antibodies targeting the programmed cell death protein-1 (PD-1) molecule have been reported to hold promising antitumor activities in patients with nasopharyngeal carcinoma (NPC). However, only a small subset of NPC patients benefits from the anti-PD-1 monotherapy and factors that affect the treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Liqin, Ma, Yuxiang, Fang, Chao, Peng, Zhuobing, Gao, Fangfang, Moll, Janne Marie, Qin, Shishang, Yu, Qichao, Hou, Yong, Kristiansen, Karsten, Fang, Wenfeng, Brix, Susanne, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428750/
https://www.ncbi.nlm.nih.gov/pubmed/36059644
http://dx.doi.org/10.3389/fonc.2022.953884
_version_ 1784779191242194944
author Xu, Liqin
Ma, Yuxiang
Fang, Chao
Peng, Zhuobing
Gao, Fangfang
Moll, Janne Marie
Qin, Shishang
Yu, Qichao
Hou, Yong
Kristiansen, Karsten
Fang, Wenfeng
Brix, Susanne
Zhang, Li
author_facet Xu, Liqin
Ma, Yuxiang
Fang, Chao
Peng, Zhuobing
Gao, Fangfang
Moll, Janne Marie
Qin, Shishang
Yu, Qichao
Hou, Yong
Kristiansen, Karsten
Fang, Wenfeng
Brix, Susanne
Zhang, Li
author_sort Xu, Liqin
collection PubMed
description Antibodies targeting the programmed cell death protein-1 (PD-1) molecule have been reported to hold promising antitumor activities in patients with nasopharyngeal carcinoma (NPC). However, only a small subset of NPC patients benefits from the anti-PD-1 monotherapy and factors that affect the treatment response need further investigation. This study aimed to examine the impact of multiple genetic and environmental factors on outcome of anti-PD-1 immunotherapy by identifying tumor size, tumor mutation burden (TMB) based on whole exon sequencing, human leukocyte antigen class I (HLA-I) homo-/heterozygosity and supertypes, blood Epstein-Barr virus (EBV) DNA load, T cell proportions, and interferon-γ(IFN-γ) levels in a cohort of 57 NPC patients that received Nivolumab or Camrelizumab treatment. Moreover, we profiled the longitudinal changes in gut microbiota composition using shotgun metagenomics sequencing. We observed that high TMB combined with HLA-I heterozygosity was associated with improved clinical outcomes. In agreement with previous studies, we found that patients with higher plasma EBV DNA load showed worse progression-free survival. We found no evidence for an effect of gut bacterial diversity on the treatment response, but identified a higher abundance of seven specific gut bacteria at baseline of non-responders, including Blautia wexlera and Blautia obeum, as well as four other bacteria belonging to the Clostridiales order, and one Erysipelatoclostridium. Combined, this study provides insight into the influence of several genetic and environmental factors on anti-PD-1 immunotherapy responses in NPC patients.
format Online
Article
Text
id pubmed-9428750
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94287502022-09-01 Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma Xu, Liqin Ma, Yuxiang Fang, Chao Peng, Zhuobing Gao, Fangfang Moll, Janne Marie Qin, Shishang Yu, Qichao Hou, Yong Kristiansen, Karsten Fang, Wenfeng Brix, Susanne Zhang, Li Front Oncol Oncology Antibodies targeting the programmed cell death protein-1 (PD-1) molecule have been reported to hold promising antitumor activities in patients with nasopharyngeal carcinoma (NPC). However, only a small subset of NPC patients benefits from the anti-PD-1 monotherapy and factors that affect the treatment response need further investigation. This study aimed to examine the impact of multiple genetic and environmental factors on outcome of anti-PD-1 immunotherapy by identifying tumor size, tumor mutation burden (TMB) based on whole exon sequencing, human leukocyte antigen class I (HLA-I) homo-/heterozygosity and supertypes, blood Epstein-Barr virus (EBV) DNA load, T cell proportions, and interferon-γ(IFN-γ) levels in a cohort of 57 NPC patients that received Nivolumab or Camrelizumab treatment. Moreover, we profiled the longitudinal changes in gut microbiota composition using shotgun metagenomics sequencing. We observed that high TMB combined with HLA-I heterozygosity was associated with improved clinical outcomes. In agreement with previous studies, we found that patients with higher plasma EBV DNA load showed worse progression-free survival. We found no evidence for an effect of gut bacterial diversity on the treatment response, but identified a higher abundance of seven specific gut bacteria at baseline of non-responders, including Blautia wexlera and Blautia obeum, as well as four other bacteria belonging to the Clostridiales order, and one Erysipelatoclostridium. Combined, this study provides insight into the influence of several genetic and environmental factors on anti-PD-1 immunotherapy responses in NPC patients. Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9428750/ /pubmed/36059644 http://dx.doi.org/10.3389/fonc.2022.953884 Text en Copyright © 2022 Xu, Ma, Fang, Peng, Gao, Moll, Qin, Yu, Hou, Kristiansen, Fang, Brix and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xu, Liqin
Ma, Yuxiang
Fang, Chao
Peng, Zhuobing
Gao, Fangfang
Moll, Janne Marie
Qin, Shishang
Yu, Qichao
Hou, Yong
Kristiansen, Karsten
Fang, Wenfeng
Brix, Susanne
Zhang, Li
Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
title Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
title_full Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
title_fullStr Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
title_full_unstemmed Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
title_short Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
title_sort genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428750/
https://www.ncbi.nlm.nih.gov/pubmed/36059644
http://dx.doi.org/10.3389/fonc.2022.953884
work_keys_str_mv AT xuliqin genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT mayuxiang genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT fangchao genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT pengzhuobing genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT gaofangfang genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT molljannemarie genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT qinshishang genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT yuqichao genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT houyong genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT kristiansenkarsten genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT fangwenfeng genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT brixsusanne genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma
AT zhangli genomicandmicrobialfactorsaffecttheprognosisofantipd1immunotherapyinnasopharyngealcarcinoma